Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients

Inclusion Criteria:

1. Participants identifying their main symptom as a burning feeling in the mid-epigastricarea and/or chest area (that is, heartburn).

2. Must have a history of symptomatic GERD for 6 months or longer prior to Screening withGERD symptoms that were responsive to acid-suppressive therapy.

3. Must have episodes of heartburn for 4 or more days during the 7 days prior to Day -1as recorded in the eDiary.

Exclusion Criteria:

1. Has a history of cancer (except basal cell carcinoma of the skin), that has not beenin remission for at least 5 years prior to Screening.

2. Has a known history of Barrett's esophagus with dysplastic changes or any changessuspicious Barrett's seen during screening endoscopy.

3. Participant developed acute upper gastrointestinal bleeding, gastric ulcer (a mucosaldefect with white coating) or duodenal ulcer (a mucosal defect with white coating),within 30 days before the start of the Screening Visit (with the possible inclusion ofthose with gastric or duodenal erosion). The participant requires chronic use (greaterthan [>] 12 doses per month) of nonsteroidal anti-inflammatory drugs (NSAIDs)including cyclooxygenase-2 (COX-2) NSAIDs within 30 days prior to the Screening Periodand throughout the study.

4. Has comorbidities that could affect the esophagus (eosinophilic esophagitis,esophageal varices, scleroderma, viral or fungal infection, esophageal strictures); ahistory of radiotherapy or cryotherapy of the esophagus; and a history of corrosive orphysiochemical injury (with the possible inclusion in the study of those withSchatzki's ring).

5. Has a history of surgical procedures that may affect the esophagus (example,fundoplication and mechanical dilatation for esophageal strictures) or a history ofgastric or duodenal surgery other than endoscopic removal of benign polyps.

6. Has erosive esophagitis (EE) as shown by endoscopy, during the Screening Period.

7. Is known to have acquired immunodeficiency syndrome (AIDS) or hepatitis, includinghepatitis virus carriers: (that is, hepatitis B surface antigen HBs-antigen (HBsAg)positive or hepatitis C virus (HCV)-antibody positive).

8. Has current or historical evidence of Zollinger-Ellison syndrome or a history ofgastric acid hypersecretion.

9. Is scheduled for surgery that requires hospitalization or requires surgical treatmentduring his/her participation in the study.

10. Has donated or lost >300 milliliter (mL) blood volume, undergone plasmapheresis, orhas had a transfusion of any blood product within 90 days prior to the first dose ofstudy drug.

11. Has a history of alcohol abuse (defined as any illicit drug use), or drug addiction inthe 12 months prior to Screening.

12. Participant with positive serology result of Helicobacter pylori (H. pylori) thatneeds eradication therapy during the study participation period as anticipated by theinvestigator.